Literature DB >> 3046469

Gerstmann-Sträussler-Scheinker disease: immunohistological and experimental studies.

J Tateishi1, T Kitamoto, H Hashiguchi, H Shii.   

Abstract

The older brother of the patient from whom the Fukuoka-1 strain was isolated was found to have numerous kuru plaques, the main finding common to both siblings. Other clinicopathological features including spongiform change were absent in the older brother. Immunostaining using anti-kuru plaque core protein and anti-beta-protein peptide revealed many kuru plaques and a few senile plaques in the older brother. Experimental transmission of the disease to laboratory animals was successful, using tissues from both siblings, through inoculation of fresh brain homogenates, purified prion protein, and formalin-fixed brain homogenates. Prion protein fractions from the patient's brain shortened the incubation periods and formalin-fixed mouse brains did not lengthen the periods. The disease in the two brothers can be classified as Gerstmann-Sträussler-Scheinker disease, a familial variant of Creutzfeldt-Jakob disease. Gerstmann-Sträussler-Scheinker disease manifests a variety of clinicopathological features. Immunohistological verification of kuru plaques has major diagnostic value in assessing dementia.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3046469     DOI: 10.1002/ana.410240108

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  14 in total

1.  The primary structure of the prion protein influences the distribution of abnormal prion protein in the central nervous system.

Authors:  T Kitamoto; K Doh-ura; T Muramoto; M Miyazono; J Tateishi
Journal:  Am J Pathol       Date:  1992-08       Impact factor: 4.307

2.  Bovine spongiform encephalopathy - a hazard to cell culture and biologically based medicines.

Authors:  R J Phillpotts
Journal:  Cytotechnology       Date:  1989-08       Impact factor: 2.058

3.  Diffuse deposition of immunohistochemically labeled prion protein in the granular layer of the cerebellum in a patient with Creutzfeldt-Jakob disease.

Authors:  H A Kretzschmar; T Kitamoto; J Doerr-Schott; P Mehraein; J Tateishi
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

4.  PrP amyloid plaques in Creutzfeldt-Jakob disease of short duration: immunohistochemical studies of 5 cases from Poland.

Authors:  P P Liberski; H Kwiecinski; M Barcikowska; B Mirecka; J Kulczycki; E Kida; P Brown; D C Gajdusek
Journal:  Eur J Epidemiol       Date:  1991-09       Impact factor: 8.082

5.  Human anti-prion antibodies block prion peptide fibril formation and neurotoxicity.

Authors:  Xing Wei; Yvonne Roettger; Bailin Tan; Yongzheng He; Richard Dodel; Harald Hampel; Gang Wei; Jillian Haney; Huiying Gu; Brian H Johnstone; Junyi Liu; Martin R Farlow; Yansheng Du
Journal:  J Biol Chem       Date:  2012-02-23       Impact factor: 5.157

6.  Effect of acetylcholinesterase inhibitors on AChE-induced PrP106-126 aggregation.

Authors:  M V Clos; M Pera; M Ratia; S Román; P Camps; D Muñoz-Torrero; L Colombo; M Salmona; A Badia
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

7.  Immunoreactivity of cerebral amyloidosis is enhanced by protein denaturation treatments.

Authors:  R Doi-Yi; T Kitamoto; J Tateishi
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

8.  Clinico-pathological correlation in dementias.

Authors:  F Teixeira; E Alonso; V Romero; A Ortíz; C Martínez; E Otero
Journal:  J Psychiatry Neurosci       Date:  1995-07       Impact factor: 6.186

9.  Species barrier prevents an abnormal isoform of prion protein from accumulating in follicular dendritic cells of mice with Creutzfeldt-Jakob disease.

Authors:  T Muramoto; T Kitamoto; M Z Hoque; J Tateishi; I Goto
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

10.  Creutzfeldt-Jakob disease with codon 129 polymorphism (valine): a comparative study of patients with codon 102 point mutation or without mutations.

Authors:  M Miyazono; T Kitamoto; K Doh-ura; T Iwaki; J Tateishi
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.